Safety and Efficacy Evaluation of S(+)-Ketamine for Postoperative Acute Pain in Adults in Perioperative Settings: A Multicenter, Randomized, Open-label, Active Controlled Pragmatic Clinical Trial
Safety and Efficacy Evaluation of S(+)-Ketamine for Postoperative Acute Pain in Adults in Perioperative Settings: A Multicenter, Randomized, Open-label, Active Controlled Pragmatic Clinical Trial
A multicenter, randomized, open-label, active controlled pragmatic clinical trial that evaluates the safety and efficacy of S (+) -ketamine for postoperative acute pain in adults in perioperative settings.
Patients often suffer acute pain after operation ,which may affect the recovery. Opioid such as morphine is the most commonly analgesic drugs, but opioid has many obviously adverse reactions ,for example respiratory depression,circulation inhibition,tolerance, addiction, nausea, vomiting, pruritus, etc. S (+) - ketamine has been described to decrease acute pain and opioid consumption,but it needs to confirm for chinese patients undergoing surgery.
Objective:Evaluate the efficacy and safety of S (+) - ketamine on acute perioperative pain for chinese adult patients,and look for the best dosage, mode of administration, timing, and compatibility ,as well explore the effect of S (+) - ketamine on postoperative delirium,anxiety ,depression and cognitive dysfunction.
Inclusion Criteria:
Exclusion Criteria:
1. The expected length of hospital stay of the patient is less than 48h;
2. Patients expected to be admitted to the ICU after surgery;
3. Patients expected to return to the ward with tracheal catheter after surgery;
4. Be allergic to S (+) - ketamine;
5. Patients with severe disorder of consciousness or mental system diseases (schizophrenia, mania, bipolar disorder, psychosis, etc.) or cognitive dysfunction;
6. Patients with a history of severe cardiovascular disease (congestive heart failure, severe angina attack, or unstable angina or myocardial infarction within 6 months);
7. Patients during pregnancy or lactation;
8. Patients with MMSE score <18 points;
9. Patients with any of the following contraindications of S (+) - ketamine:
wwdd1962@aliyun.com8613381082966
301wh@163.com8613661363231